Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 8, 2006, Pages 716-718

  Kroidl, A ^a   Huck, K ^b   Weinspach, S ^b   Gudowius, S ^b   MacKenzie, C R ^c   Oette, M ^a   Haussinger D ^a   Niehues, T ^b  

^a Clinic for Gastroenterology   (Germany)

^b Clinic for Paediatric Oncology Haematology and Immunology   (Germany)

^c University Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; BCG VACCINE; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; GANCICLOVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ANEMIA; ARTICLE; BACTERIUM CULTURE; BODY WEIGHT DISORDER; BRONCHOPNEUMONIA; BRONCHOSCOPY; CASE REPORT; DRUG POTENTIATION; FEVER; FOLLOW UP; GRANULOMATOUS INFLAMMATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER TOXICITY; LUNG INFILTRATE; LUNG TUBERCULOSIS; LYMPHADENITIS; MALE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; PRESCHOOL CHILD; RECURRENT DISEASE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BCG VACCINE; HIV; HIV INFECTIONS; HUMANS; INFANT; INFLAMMATION; MALE; SYNDROME; TUBERCULOSIS;

EID: 33746605974     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540500452473     Document Type: Article

References (20)

1. Colditz, GA and Brewer, TF and Berkey, CS and Wilson, ME and Burdiek, E and Fiueberj, HV and (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature JAMA, 271, pp. 698-702.
2. Udani, PM. (1994) BCG vaccination in India and tuberculosis in children: newer facets Indian J Pediatr, 61, pp. 451-62.
3. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004;79:27-38.
4. FinePEM, CarneiroIAM, MilstienJB, ClementsCJ. Issues relating to the use of BCG immunization programmes - a discussion document. World Health Organization (WHO) document no. WHO/V&B/99.23. Geneva: WHO, 1999.
5. Milstien, JB and Gibson, JJ. (1990) Quality control of BCG by WHO: A review of factors that may influence vaccine effectiveness and safety Bull World Health Organ, 68, pp. 93-108.
6. Lotte, A and Wasz-Hockert, O and Poisson, N and Engbaek, H and Landmann, H and Quast, U and (1988) Second IUATLD study on complications induced by intradermal BCG vaccination Bull Int Union Tuberc Lung Dis, 63, pp. 47-59.
7. Talbot, EA and Perkins, MD and Silva, SF and Frothingham, R. (1997) Disseminated Bacille Calmette-Guerin disease after vaccination: Case report and review Clin Infect Dis, 24, pp. 1139-46.
8. Richter, E and Weizenegger, M and Rüsch-Gerdes, S and Niemann, S. (2003) Evaluation of genotype MTBC assay for differentiation of clinical Mycobacterium tuberculosis complex isolates J Clin Microbiol, 41, pp. 2672-5.
9. Lumb, R and Shaw, D. (1992) Mycobacterium bovis (BCG) vaccination: progressive disease in a patient asymptomatically infected with the human immunodeficiency virus Med J Aust, 156, pp. 286-7.
10. Smith, E and Thybo, S and Bennedsen, J. (1992) Infection with Mycobacterium bovis in a patient with AIDS: A late complication of BCG vaccination Scand J Infect Dis, 24, pp. 109-10.
11. Hofstadler, G and Schmitt, K and Tulzer, G and Binder, L and Brandstetter, B. (1998) BCG lymphadenitis in an HIV-infected child 9.5 y after vaccination AIDS Patient Care STDS, 12, pp. 677-80.
12. Marks, K and Amitai, Y and Engelhard, D and Kori, M and Maayan, S. (1993) Mycobacterium bovis lymphadenitis complicating BCG immunization in an infant with symptomatic HIV-1 infection Isr J Med Sci, 29, pp. 381-2.
13. Puthanakit, T and Oberdorfer, P and Punjaisee, S and Wannarit, P and Sirisanthana, T and Sirisanthana, V. (2005) Immune reconstitution syndrome due to Bacillus Calmette-Guerin after initiation of antiretroviral therapy in children with HIV infection Clin Infect Dis, 41, pp. 1049-52.
14. Sharp, MJ and Mallon, DF. (1998) Regional Bacillus Calmette-Guerin lymphadenitis after initiating antiretroviral therapy in an infant with human immunodeficiency virus type 1 infection Pediatr Infect Dis, 17, pp. 660-2.
15. Armbruster, C and Junker, W and Vetter, N and Jaksch, G. (1990) Disseminated bacille Calmette-Guerin infection in an AIDS patient 30 years after BCG vaccination J Infect Dis, 162, pp. 1216.
16. Hesseling, AC and Schaaf, HS and Hanekom, WA and Beyers, N and Cotton, MF and Gie, RP and (2003) Danish Bacille Calmette-Guerin vaccine-induced disease in human immunodeficiency virus-infected children Clin Infect Dis, 37, pp. 1226-33.
17. Archibald, LK and Kazembe, PN and Nwanyanwu, O and Mwansambo, C and Reller, LB and Jarvis, WR. (2003) Epidemiology of bloodstream infections in a Bacille Calmette-Guerin-vaccinated paediatric population in Malawi J Infect Dis, 188, pp. 202-8.
18. Waddell, RD and Lishimpi, K and Von Reyn, CF and Chintu, C and Baboo, KS and Kreiswirth, B and (2001) Dartmouth/UCLMS/UNZA Collaborative Study Group. Bacteraemia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Guerin (BCG) among HIV-positive children and adults in Zambia AIDS, 15, pp. 55-60.
19. Wayne, LG. (1982) Microbiology of tubercle bacilli Am Rev Respir Dis, 125, pp. 31-41.
20. Talbot, EA and Williams, DL and Frothingham, R. (1997) PCR identification of Mycobacterium bovis BCG Journal of Clinical Microbiology, 35, pp. 566-9.